deltoid or the vastus lateralis. The vaccine should not be injected into the gluteal area.

Adrenaline injection must be kept readily available following immunization, should an anaphylactic or other allergic reaction occur due to any component of the vaccine

PRESENTATIONS:

Vial pack

- 0.5 ml Single dose container
- 2.5 ml Multidose container (For Maximum 5 withdrawal)
- 5.0 ml Multidose container (For Maximum 10 withdrawal)
- 0.5 ml PFS with needle - Single dose

Store at 2°C to 8°C,
Do not freeze.
Keep out of reach of children

To report adverse events, call toll free on 1800 419 1141 or visit www.zyduslife.com

® Registered Trademark

zydus

2091162

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Typhoid Polysaccharide Vaccine IP

Vactyph®

COMPOSITION:

Each dose of 0.5 ml contains :

Purified Vi Capsular polysaccharide of *S. typhi*	0.025 mg
Phenol as preservative maximum	0.25 % w/v
Isotonic buffer solution	q.s.

DESCRIPTION:

VACTYPH® is a colorless clear sterile solution containing the purified cell surface Vi capsular polysaccharide of Salmonella typhi.

INDICATIONS:

VACTYPH® is indicated for active immunisation against typhoid fever in adults and children over 2 years of age.

Size : 96 x 100 mm (L x H)

Colour : CMYK

\\mfgfilecl\PTC\Pkg. Dev\Commercial\ARTWORKS_COM\Domestic New logo 2022\VACTYPH\2091162_PI Vactyph Inj 0.5ml Sale Domestic

CONTRAINDICATIONS:
VACTYPH® should not be administered to persons with a history of hypersensitivity to any component of this vaccine.

PRECAUTIONS & WARNINGS:
The administration of VACTYPH® should be deferred if fever or acute infection is present. The vaccine should not be administered intravenously. It should be shaken well before use & should not be used if frozen. The vaccine may not produce the desired response in immunosuppressed persons or persons receiving immunosuppressive therapy. As with any other intramuscular injection, VACTYPH® should be given with caution to individuals with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection.

USAGE IN PREGNANCY, LACTATION & CHILDREN:
Since it is not known whether the vaccine can cause fetal harm when administered to a pregnant woman, it should be given to such ladies only if clearly needed. When possible, delaying vaccination until the second or third trimester to minimize the possibility of teratogenicity is a reasonable precaution. It is not known if the vaccine is excreted in human milk. There is also no data to warrant the use of this product in nursing mothers for passive antibody transfer to an infant. Safety and effectiveness of Purified Vi Capsular Polysaccharide Typhoid Vaccine has not been established in children below the age of 2 years.

ADVERSE REACTIONS:
VACTYPH® is usually very well tolerated. However, mild local pain, rash, local induration or mild fever may occur occasionally.

DOSAGE AND ADMINISTRATION:
The recommended dose of VACTYPH® in all age groups is a single dose of 0.5ml administered intramuscularly. The dose for adults is given intramuscularly in the deltoid muscles and in children in the